Cortisol is a human glucocorticoid hormone that is essential for survival under periods of stress. In 1949, exogenous glucocorticoid supplementation for patients with rheumatoid arthritis was shown to provide pain relief. This discovery led to the recognition that glucocorticoids have potent anti-inflammatory and immunosuppressive effects and fuelled their use as therapeutics in a variety of immune-associated disorders and to prevent organ transplant rejection. At present, ~1% of the general population receive oral glucocorticoids, with this prevalence increasing to 2.5% among older adults aged 70–79 years. Glucocorticoid use has gained prominence during the COVID-19 pandemic as dexamethasone, one of the most potent glucocorticoid drugs available on the market, is effective in the treatment of patients with severe COVID-19 (REF) (BOX 1).

Despite excellent therapeutic efficacy for the treatment of inflammatory disorders, long-term glucocorticoid therapy is limited by a wide range of adverse effects. Relevant to this Review, glucocorticoids precipitate the development of hyperglycaemia, insulin resistance, dyslipidaemia, central adiposity and hepatic steatosis. Over time, these metabolic effects result in diabetes mellitus (alternately referred to as 'steroid diabetes'), one of the most well-established adverse effects of hyperglucocorticoidism. Globally, oral glucocorticoid use is linked to 2% of cases of new-onset diabetes mellitus. When glucocorticoids were administered for 1–7 days to healthy individuals, insulin resistance and impaired glucose homeostasis were observed. Furthermore, a meta-analysis found that, in patients without pre-existing diabetes mellitus who were treated with glucocorticoids for more than 1 month, the incidence of glucocorticoid-induced hyperglycaemia is ~32% and the incidence of diabetes mellitus is 19%.

In patients with pre-existing diabetes mellitus, hyperglycaemia can be exacerbated by starting glucocorticoid treatment. Of note, in Cushing syndrome, endogenous overproduction of cortisol produces similar complications to those of iatrogenic hypercortisolism.
The prevalence of diabetes mellitus among patients with endogenous Cushing syndrome is 20–45%, with an additional 10–30% of patients exhibiting impaired glucose tolerance13. Despite the widespread use of glucocorticoids and their tight association with hyperglycaemia and diabetes mellitus, a firm understanding of the underlying mechanisms and strategies to mitigate and manage these adverse effects are lacking. The actions of glucocorticoids are predominately mediated by the glucocorticoid receptor, which is localized in the cytoplasm of target tissues17. Upon glucocorticoid binding, the glucocorticoid receptor translocates to the nucleus and can directly bind as a homodimer to DNA sequences called glucocorticoid-response elements (GREs), which are located throughout the genome17. This binding to GREs is facilitated by co-regulatory proteins and histone modifiers. In addition, the ligand-bound glucocorticoid receptor can tether to other transcription factors to indirectly upregulate or downregulate gene expression17. Studies into mechanisms and treatments to minimize or prevent glucocorticoid-induced diabetes mellitus are ongoing and eagerly anticipated to improve the clinical experience of glucocorticoid users17.

In this Review, we summarize the epidemiology of glucocorticoid-induced hyperglycaemia and our current understanding of the diabetogenic actions of glucocorticoids within different organs that contribute to the development of glucocorticoid-induced diabetes mellitus. We then discuss current diagnostic criteria and treatment options based on the type and schedule of glucocorticoid and the degree of hyperglycaemia established. Finally, we provide novel insights into promising preclinical approaches and potential targets on the horizon that could eliminate the diabetogenic effects of glucocorticoid drugs while preserving their anti-inflammatory effects.

### Epidemiology

Exposure to even a single dose of exogenous glucocorticoids is associated with an abnormal elevation in blood concentrations of glucose in patients with or without pre-existing diabetes mellitus19,20. Indeed, glucocorticoids exacerbate hyperglycaemia in a dose-dependent manner irrespective of prior history of diabetes mellitus21,22. A retrospective review reported that 56% of hospitalized patients without a history of diabetes mellitus experienced at least one episode of hyperglycaemia (defined as blood glucose levels ≥200 mg/dl) after corticosteroid treatment21. In patients treated with glucocorticoids for respiratory disease4, renal disease5, cancer6, solid organ transplant27 and rheumatoid arthritis28, the incidence of new-onset glucocorticoid-induced diabetes mellitus ranges between 15% and 40%. Moreover, the incidence of glucocorticoid-induced hyperglycaemia might be underestimated because of a reliance on fasting blood levels of glucose for diagnosis (discussed later).

### Effects of drug type and dosing regimen

The relative risk of any individual developing glucocorticoid-induced hyperglycaemia and diabetes mellitus is difficult to predict owing to the combination of doses, variable glucocorticoid potencies, routes of administration and duration of treatment that are used for different diseases. For the purpose of this Review, we use the following definitions: acute treatment, up to 24 h; short-term treatment, between 24 h to 2 weeks; long-term treatment, 2 weeks to 6 months or longer). Glucocorticoid preparations on the market vary in their pharmacological properties and duration of anti-inflammatory action29. Relative to short-acting hydrocortisone (half-life of 8 h), intermediate-acting prednisolone (half-life of 16–36 h) and methylprednisolone (half-life of 18–40 h), which are the most commonly used glucocorticoids, are 4–5-fold more potent in their anti-inflammatory effect13,29. The long-acting dexamethasone and betamethasone (both with a half-life of 36–54 h) are 25-fold more potent than hydrocortisone11,29.

All common routes of administration for glucocorticoids (oral, inhalation and topical) are linked to an increased risk of hyperglycaemia when prescribed at high doses21,20–32, yet oral corticosteroids confer the greatest risk due to their systemic exposure22. Local injections of glucocorticoids (intra-articular or intra-lesional) also increase hyperglycaemia in patients with controlled diabetes mellitus34,35. Glucocorticoids exert dose-dependent effects as demonstrated by odds ratios for eventual hypoglycaemic intervention (over a 90-day period) that ranged between 1.7 and 10.3 for daily oral hydrocortisone-equivalent doses starting at 20 mg per day and increasing to ≥120 mg per day, respectively22. In patients who underwent an organ transplant, the...
risk of developing post-transplant diabetes mellitus was also found to increase by 5% per 0.01 mg/kg per day increase in prednisolone dose administered by intravenous injection. Inhaled corticosteroids used at high doses (fluticasone at ≥1,000 µg per day) increased the incidence of diabetes mellitus by 34% in patients with respiratory disease. A positive correlation was also observed between the relative potency of a prescribed topical glucocorticoid and the incidence of diabetes mellitus in case–control studies of adults in Denmark and the UK. Dosing regimen also contributes substantially to the precipitation of diabetes mellitus as the incidence of hyperglycaemia was 50% more frequent in patients with haematological diseases who received long-term continuous administration of glucocorticoids over 6-weeks compared with cyclic administration (5 days on, 15 days off). Patients without a history of diabetes mellitus who experienced multiple episodes of hyperglycaemia after glucocorticoid therapy were found to be on comparatively longer corticosteroid regimens than those who experienced ≤1 episode of hyperglycaemia.

Other risk factors
Many factors are associated with the susceptibility of patients on glucocorticoid therapy to develop hyperglycaemia and diabetes mellitus (BOX 2). Older age (>60 years) is tightly linked to an increased risk of glucocorticoid-induced diabetes mellitus due to declining pancreatic β-cell function and increased glucose intolerance with age. High BMI (>25 kg/m²), abdominal obesity and hypertriglyceridaemia are other independent risk factors that contribute to glucocorticoid-induced diabetes mellitus. In addition, prior reductions in insulin sensitivity or deficient glucose-stimulated insulin secretion (GSIS), prior glucose intolerance or impaired fasting levels of glucose, and high HbA₁c values (≥6.0%) are further indicators of increased risk of glucocorticoid-induced diabetes mellitus.

The extent to which a family history of diabetes mellitus contributes to new-onset glucocorticoid-induced diabetes mellitus is still not clear. Several studies do report a positive link to a family history of diabetes mellitus. In a study that compared a cohort of patients with glucocorticoid-induced diabetes mellitus to patients with type 2 diabetes mellitus (T2DM), a family history of diabetes mellitus was found in 35% versus 65% of patients, respectively. In 2021, specific single-nucleotide polymorphisms were shown to correlate with the development of hyperglycaemia in children receiving dexamethasone for the treatment of acute lymphoblastic leukaemia. Mechanistically, the single-nucleotide polymorphisms modified the genomic binding of the glucocorticoid receptor to metabolic genes in adipose and liver cells. Although these data are intriguing, they will need to be replicated in larger cohorts.

Other less well-studied risk factors include impaired renal function (estimated glomerular filtration rate <40 ml/min/1.73 m²), presence of hypertension, cytomegalovirus infection, smoking, history of hypertension, specific single-nucleotide polymorphisms (mycophenolate mofetil or calcineurin inhibitors) or diuretic (furosemide) medication therapy. Other factors include smoking, cytomegalovirus infection, current smoking, and race and ethnicity. No consistent sex differences were observed in glucocorticoid-induced insulin resistance in healthy individuals or hospital inpatients. However, a trend was observed towards an increased incidence of glucocorticoid-induced hyperglycaemia in hospitalized men. The incidence of glucocorticoid-induced hyperglycaemia might also be confounded by the use of concomitant immunosuppressive or diuretic medications. Patients who underwent an organ transplant and received calcineurin inhibitors concurrent with glucocorticoid therapy would be expected to show more severe glucose intolerance than those not on calcineurin inhibitors due to the suppressive effect of calcineurin inhibitors on insulin production. Similarly, the concurrent use of the immunosuppressant mycophenolate mofetil with high-dose prednisolone treatment (≥1 mg/kg per day) in patients with systemic lupus erythematosus was associated with the development of diabetes mellitus, possibly explained by pancreatic β-cell dysfunction and impaired insulin secretion. Thus, several predictors beyond glucocorticoid potency, dose and dosing schedule should be considered when estimating the risk of developing glucocorticoid-induced diabetes mellitus.

Pathophysiology
The development of glucocorticoid-induced hyperglycaemia involves stimulation of hepatic glucose production and increased adipose tissue lipolysis followed by the development of whole-body insulin resistance as well as impaired production and secretion of insulin by pancreatic β-cells. Many of these effects are mediated by direct actions of the glucocorticoid receptor, which binds to specific target genes and controls their transcriptional expression. As described in this section, the tissue-specific effects of glucocorticoids contribute to amplifying their whole-body diabetogenic effect in vivo through inter-organ signalling (FIG. 1).

Liver
Hepatic gluconeogenesis. The liver serves as a central node that links nutritional and hormonal cues to whole-body glucose homeostasis. When circulating glucose is scarce, the liver maintains euglycaemia by increasing gluconeogenesis and glycogenolysis. During a period of stress, glucocorticoids promote increased liver glucose output to ensure that the organism has enough glucose to fuel the brain and survive. In response to increased
Glucocorticoids increase appetite and promote the intake of high-calorie (high-fat and/or high-sugar) ‘comfort food’, which indirectly promotes obesity and diabetes mellitus. Glucocorticoids upregulate the transcriptional and functional activity of neuropeptide Y (NPY)-agouti-related peptide (AgRP) neurons in the arcuate nucleus of the hypothalamus and promote leptin resistance. Skeletal muscle atrophy results from glucocorticoid-mediated protein degradation and decreased protein synthesis in myocytes, and glucocorticoids also decrease glucose uptake into these cells. In the liver, glucocorticoids act directly to upregulate enzymes involved in gluconeogenesis and promote hepatic insulin resistance, which together accelerate the development of hyperglycaemia. Furthermore, glucocorticoids synergize with insulin to stimulate non-esterified fatty acid (NEFA) uptake by hepatocytes and triglyceride synthesis in the liver, which causes hepatic steatosis. In adipose tissue, glucocorticoids increase adipogenesis, de novo lipogenesis and triglyceride synthesis as well as lipid uptake and storage. Concurrently, glucocorticoids facilitate lipolysis, which promotes the futile cycling of lipids. Glucocorticoids also decrease glucose uptake into adipocytes. Acute exposure of pancreatic β-cells to glucocorticoids can stimulate insulin secretion and β-cell hyperplasia to counterbalance glucocorticoid-induced insulin resistance and to maintain plasma levels of glucose within the physiological range. However, long-term exposure to glucocorticoids can interfere with insulin biosynthesis and secretion and induce β-cell apoptosis. Osteocalcin is secreted by osteoblasts and circulating osteocalcin from bone promotes insulin secretion by β-cells. Glucocorticoids suppress the expression of osteocalcin, thereby indirectly inhibiting insulin secretion. The increase in circulating levels of amino acids from muscle breakdown and NEFAs and glycerol from adipose tissue lipolysis provide substrates to the liver for gluconeogenesis. High plasma levels of NEFAs also accumulate ectopically in skeletal muscle, liver and β-cells, which further exacerbates insulin resistance. Thick solid arrows indicate effects; thin solid arrows indicate a transition in time; dashed arrows indicate secreted factors.

**Hepatic insulin resistance.** A second key pathway contributing to glucocorticoid-induced hyperglycaemia is the development of hepatic insulin resistance. Under normal physiological conditions, insulin potently suppresses hepatic gluconeogenesis. However, in the presence of glucocorticoids, hepatic insulin resistance occurs, which enables gluconeogenesis to proceed unopposed due to the loss of insulin-mediated repression. Mechanistically, the phosphorylation of downstream signalling messengers of the insulin cascade (that is, insulin receptor substrates (IRSs), phosphatidylinositol 3-kinase (PI3K) and protein kinase B (PKB–AKT)) was found to be impaired in rats treated with glucocorticoids. Despite glucocorticoid-induced insulin resistance occurring within the gluconeogenic pathway, the pro-lipogenic effect of insulin remains intact. Compensatory hyperinsulinaemia occurs in response to glucocorticoid-induced hyperglycaemia and, when this condition is paired with increased hepatic glucose delivery (from glucocorticoid-induced peripheral insulin resistance), synergistic stimulation of de novo lipogenesis and subsequent hepatic steatosis occurs, which in turn exacerbates hepatic insulin resistance in a vicious feed-forward cycle in both humans and animal models. Increased liver uptake of circulating non-esterified fatty acids (NEFAs) in the presence of glucocorticoids further precipitates gluconeogenesis and hepatic steatosis. Glucocorticoids also stimulate the biosynthesis of ceramide in the liver, a sphingolipid that is highly associated with hepatic insulin resistance.

**Skeletal muscle**

**Muscle insulin signalling and glucose uptake.** Skeletal muscle is the primary site where insulin-stimulated glucose uptake and glycogen storage occur postprandially. Glucocorticoids can directly disrupt insulin signalling in skeletal muscle by downregulating the expression and phosphorylation of IRS1, PI3K and PKB–AKT as shown in rats. This effect results in concomitant inhibition of insulin-induced recruitment of glucose transporter 4 (GLUT4) to the cell surface of skeletal muscle. In mouse myotubes, GREs were identified in numerous genes that affect insulin signalling (such as *Pik3r1*, which encodes the p85α subunit of PI3K). Increases in p85α abundance disrupt its normal interaction with IRS1. This disruption in insulin signalling indirectly decreases glycogen synthase kinase 3 phosphorylation, which clinically manifests as decreased levels of muscle glycogen occurring in patients who receive glucocorticoids after transplantation. Thus, glucocorticoid exposure dampens skeletal muscle insulin sensitivity and glucose uptake, which contributes to the development of glucocorticoid-induced diabetes mellitus.

**Development of myopathy.** Patients under long-term exposure to glucocorticoid drugs (the length of time until muscle effects occur depends on dose but is generally 2–4 weeks) experience extensive skeletal muscle atrophy that results in the development of myopathy. Muscle mass is reduced by the combined effect of glucocorticoids to promote protein degradation within skeletal muscle while blunting protein synthesis. Glucocorticoids act by abolishing the transport of amino acids into muscle and also inhibit myogenesis by downregulating myogenin, therefore limiting protein synthesis. Furthermore, the stimulatory actions of insulin and insulin-like growth factor 1 (IGF1) on muscle anabolism are repressed by glucocorticoids through the inhibition of PKB–AKT phosphorylation and mammalian target of rapamycin (mTOR) phosphorylation. Synchronously, proteolysis is facilitated by glucocorticoid-mediated upregulation of atrophy-related gene networks in C2C12 mouse myotubes. **Hepatic insulin resistance.** A second key pathway contributing to glucocorticoid-induced hyperglycaemia is the development of hepatic insulin resistance. Under normal physiological conditions, insulin potently suppresses hepatic gluconeogenesis. However, in the presence of glucocorticoids, hepatic insulin resistance occurs, which enables gluconeogenesis to proceed unopposed due to the loss of insulin-mediated repression. Mechanistically, the phosphorylation of downstream signalling messengers of the insulin cascade (that is, insulin receptor substrates (IRSs), phosphatidylinositol 3-kinase (PI3K) and protein kinase B (PKB–AKT)) was found to be impaired in rats treated with glucocorticoids. Despite glucocorticoid-induced insulin resistance occurring within the gluconeogenic pathway, the pro-lipogenic effect of insulin remains intact. Compensatory hyperinsulinaemia occurs in response to glucocorticoid-induced hyperglycaemia and, when this condition is paired with increased hepatic glucose delivery (from glucocorticoid-induced peripheral insulin resistance), synergistic stimulation of de novo lipogenesis and subsequent hepatic steatosis occurs, which in turn exacerbates hepatic insulin resistance in a vicious feed-forward cycle in both humans and animal models. Increased liver uptake of circulating non-esterified fatty acids (NEFAs) in the presence of glucocorticoids further precipitates gluconeogenesis and hepatic steatosis. Glucocorticoids also stimulate the biosynthesis of ceramide in the liver, a sphingolipid that is highly associated with hepatic insulin resistance.

**Skeletal muscle**

**Muscle insulin signalling and glucose uptake.** Skeletal muscle is the primary site where insulin-stimulated glucose uptake and glycogen storage occur postprandially. Glucocorticoids can directly disrupt insulin signalling in skeletal muscle by downregulating the expression and phosphorylation of IRS1, PI3K and PKB–AKT as shown in rats. This effect results in concomitant inhibition of insulin-induced recruitment of glucose transporter 4 (GLUT4) to the cell surface of skeletal muscle. In mouse myotubes, GREs were identified in numerous genes that affect insulin signalling (such as *Pik3r1*, which encodes the p85α subunit of PI3K). Increases in p85α abundance disrupt its normal interaction with IRS1. This disruption in insulin signalling indirectly decreases glycogen synthase kinase 3 phosphorylation, which clinically manifests as decreased levels of muscle glycogen occurring in patients who receive glucocorticoids after transplantation. Thus, glucocorticoid exposure dampens skeletal muscle insulin sensitivity and glucose uptake, which contributes to the development of glucocorticoid-induced diabetes mellitus.

**Development of myopathy.** Patients under long-term exposure to glucocorticoid drugs (the length of time until muscle effects occur depends on dose but is generally 2–4 weeks) experience extensive skeletal muscle atrophy that results in the development of myopathy. Muscle mass is reduced by the combined effect of glucocorticoids to promote protein degradation within skeletal muscle while blunting protein synthesis. Glucocorticoids act by abolishing the transport of amino acids into muscle and also inhibit myogenesis by downregulating myogenin, therefore limiting protein synthesis. Furthermore, the stimulatory actions of insulin and insulin-like growth factor 1 (IGF1) on muscle anabolism are repressed by glucocorticoids through the inhibition of PKB–AKT phosphorylation and mammalian target of rapamycin (mTOR) phosphorylation. Synchronously, proteolysis is facilitated by glucocorticoid-mediated upregulation of atrophy-related gene networks in C2C12 mouse myotubes.
myoblasts, including Fbxo32 (encoding atrogin 1) and Trim63 (encoding MuRF1), members of the ubiquitin–proteasome system. Myostatin, a secreted factor that promotes muscle catabolism, is concurrently upregulated by glucocorticoids and attenuates the proliferation and differentiation of myoblasts. The effects of glucocorticoids on skeletal muscle were verified in healthy individuals who were treated for 3–6 days with high doses of glucocorticoid; in these individuals, serum levels of amino acids were elevated due to enhanced muscle proteolysis and blunted protein anabolism.

Increases in circulating levels of amino acids also indirectly hinder insulin-stimulated glucose transport and glycogen synthesis in muscle tissue. As described later, glucocorticoids also increase the circulation of NEFAs from adipose tissue lipolysis and the ectopic accumulation of NEFAs in skeletal muscle further exacerbates insulin resistance. Moreover, the elevation of serum amino acids and NEFAs from glucocorticoid exposure provides substrates to the liver for gluconeogenesis.

**White adipose tissue**

Aberrant adipose tissue distribution and truncal obesity are hallmark clinical characteristics of patients with hypercortisolism. Lipid redistribution from peripheral to abdominal adipose depots suggests that glucocorticoids induce depot-dependent adipose tissue breakdown and expansion, although the mechanisms are not fully understood. Central obesity is linked to insulin resistance and the development of T2DM due to the anatomical location of hypertrophic WAT near the liver and direct drainage of NEFAs and pro-inflammatory factors into the portal circulation. Glucocorticoids promote adipogenesis, triglyceride synthesis and adipose hypertrophy, preferentially in the abdominal adipose depot. Of note, glucocorticoids are also an essential component of the differentiation cocktail used to transform preadipocytes into mature adipocytes in vitro. In mouse 3T3-L1 adipocytes, GREs are present near a wide range of genes involved in adipogenesis, de novo lipogenesis, triglyceride synthesis, and lipid transport and storage. In addition, the transcription factor Forkhead box A3 (a direct target of glucocorticoid receptor) binds to promoters of glucocorticoid receptor-regulated genes related to lipid metabolism and facilitates glucocorticoid receptor binding via chromatin remodelling, which leads to adipose expansion.

**Lipid metabolism.** Although de novo lipogenesis is only a minor contributor to the overall pool of triglycerides in adipose tissue, glucocorticoids can amplify lipogenesis in the presence of insulin. The additive or synergistic effect of glucocorticoids and insulin has also been shown to increase the expression and activity of lipoprotein lipase, an enzyme that hydrolyses circulating triglyceride-rich lipoproteins and provides local free fatty acids that are taken up by adipocytes. Glucocorticoids have a greater effect on lipoprotein lipase in visceral versus subcutaneous adipose depots, thereby promoting lipid accumulation specifically in the abdominal region.

Intriguingly, despite contributing to lipid expansion, glucocorticoids concurrently increase triglyceride hydrolysis through upregulation of hormone-sensitive lipase and monoacylglycerol lipase, which promotes the futile cycling of lipids. The expression of genes involved in lipolysis is regulated by the direct binding of glucocorticoid receptors to GREs within these genes or indirectly via other transcription factors, including FOXO1 and FOXO3. Glucocorticoids also promote lipolysis through upregulation of ANGPTL4, which encodes angiopoietin-like 4, an adipokine that stimulates the production of intracellular AMP in adipocytes. NEFA release is amplified by the permissive action of glucocorticoids on β-adrenergic-stimulated lipolysis, which occurs concurrently with the loss of insulin-mediated inhibition of lipolysis due to insulin resistance. Although some discrepant results have been reported in the literature (probably due to the concentration, duration of glucocorticoid treatment, adipose depot and/or species differences), short-term infusions of glucocorticoids (6–11 h) in humans increase serum levels of NEFA and glycerol. Increased levels of NEFA and glycerol promote hyperglycaemia by accelerating hepatic gluconeogenesis and impairing liver and muscle insulin sensitivity from ectopic lipid accumulation.

**Insulin sensitivity.** The effects of glucocorticoids on adipose tissue insulin sensitivity are species dependent. In rodent models, glucocorticoids decrease the phosphorylation of factors downstream of insulin receptor (IRS1, PI3K and PKB–AKT) and decrease insulin-receptor stimulated GLUT4 translocation. By contrast, increased insulin signalling and glucose uptake were observed with short-term (from 24 h to 7 days) glucocorticoid administration to human subcutaneous adipocytes. Notably, in humans, the subcutaneous adipose depot is comparatively sensitive to insulin relative to the insulin-resistant visceral adipose depot, independent of glucocorticoid use.

Glucocorticoids also indirectly affect whole-body insulin sensitivity by regulating the levels of adipokines secreted by WAT. For example, leptin and resistin are upregulated by glucocorticoids in WAT and promote insulin resistance.

**WAT inflammation.** Another consideration is the effect of glucocorticoids on adipose tissue inflammation. Adipose tissue macrophages are associated with insulin resistance in obesity. As glucocorticoids are globally anti-inflammatory, it is interesting that glucocorticoid treatment induces adipocyte hypertrophy and insulin resistance without increasing M1-like pro-inflammatory macrophage infiltration in adipose tissue under conditions of high-fat diet-induced obesity in mice. Interestingly, glucocorticoids were shown to influence mouse primary peritoneal macrophage polarization in vitro, increasing M2-like macrophage markers (Cd206) and decreasing M1-like macrophage markers (Il16). In line with this observation, corticosterone treatment in mice promoted M2-macrophage infiltration into visceral (but not subcutaneous) adipose tissue, which was linked to impaired insulin sensitivity under a normal chow diet.
Further studies are warranted to better understand the mechanism of this macrophage–adipose tissue crosstalk.

**Other adipose depots**

**Thermogenic adipose tissue.** Brown adipocytes in brown adipose tissue (BAT) differ morphologically and functionally from white adipocytes in WAT by the presence of a high number of mitochondria, which promote non-shivering thermogenesis through the expression of UCP1. A third type of adipocyte, known as beige (or ‘brite’) adipocytes, is derived from the white adipocyte lineage and located within WAT, yet also expresses UCP1 (REFS 100,101).

A growing body of evidence, primarily from animal models, has demonstrated the potential of targeting BAT and the browning of WAT to combat obesity and T2DM 102. In rodents, glucocorticoids are known inhibitors of BAT and beige adipose tissue function that act, in part, to suppress energy expenditure by downregulating Ucp1 (REFS 100,101). Suppression of Ucp1 is enhanced by the overexpression of 11β-HSD1 in mouse primary brown adipocytes 103. This suppressive action of glucocorticoids is mediated by a regulatory region between −4 kb and 0 kb upstream of the Ucp1 transcription start site as shown in mouse primary brown adipocytes 104. Glucocorticoids can also indirectly suppress Ucp1 by inhibiting adrenocorticotrophic hormone (ACTH) secretion via feedback inhibition on the hypothalamic–pituitary–adrenal axis, and ACTH has been found to promote UCP1-dependent respiration in mouse primary brown adipocytes 105. Whether the glucocorticoid-mediated downregulation of Ucp1 gene expression translates to a true decrease in the thermogenic capacity of BAT remains to be clarified 106. Intriguingly, acute glucocorticoid treatment in humans (three doses over 24 h) increased BAT activation (assessed by measuring supraclavicular skin temperature and cold-induced 18F-fluorodeoxyglucose uptake in BAT depots assessed by PET–CT), whereas long-term treatment (2 weeks) suppressed glucose uptake in BAT compared with control individuals 106. Whether reversing glucocorticoid-associated suppression of BAT and WAT browning is sufficient to improve insulin sensitivity and obesity in humans remains to be determined.

**Bone marrow adipose tissue.** Adipocytes residing within the bone marrow have gained attention in the past decade as they were found to have a permissive role in contributing to metabolic diseases. Bone marrow adipose tissue (BMAT) is hypothesized to be metabolically distinct from BAT and WAT and accounts for ~70% of bone marrow volume, where BMAT critically functions to fill the long bone cavities in adult humans 107. However, the metabolic contribution of BMAT to whole-body metabolism remains poorly understood. Lipid content in bone marrow of premenopausal women is inversely correlated with whole-body insulin sensitivity 108. Moreover, decreased BMAT insulin responsiveness was reported in patients with obesity and T2DM 109. Glucocorticoids promote BMAT lipid accumulation without affecting glucose uptake into BMAT adipocytes, re-emphasizing the site-specific actions of glucocorticoids in adipose depots 109. A better understanding of the effect of glucocorticoids in BMAT remains an exciting avenue for further investigation.

**Pancreatic β-cells**

Pancreatic β-cell dysfunction underlies the progression to T2DM 110. Under acute physiological and/or pathological stress, where the demand for insulin is increased, β-cells adapt by enhancing their functional capacity to maintain euglycaemia within a narrow range. Long-term β-cell stress can result in systemic insulin resistance, which is later superseded by β-cell failure and consequent hyperglycaemia 111. Studies that investigate the effects of glucocorticoids in isolated primary islets or in vitro systems are therefore unable to account for the adaptive responses observed in vivo.

**In vitro and ex vivo studies.** An inhibitory role of glucocorticoids on β-cell function was demonstrated using in vitro cell lines and rodent-derived pancreatic islets after acute (minutes to hours) treatment with glucocorticoids 111,112. In rat insulinoma INS-1E cells, glucocorticoids had a minimal effect on basal insulin release in physiological conditions, the uptake of glucose by β-cells causes an increase in intracellular ATP levels that triggers closure of the ATP-sensitive K+ channels followed by depolarization of the β-cell membrane. This change in voltage enables the influx of Ca2+ and subsequent exocytosis of insulin granules 111,112. Glucocorticoids are thought to interfere at several stages in this process by limiting glucose uptake and oxidation, facilitating futile cycling of glucose, repolarizing the β-cell membrane by enhancing K+ channel activity and in turn attenuating Ca2+ influx, and amplifying α2-adrenergic signalling 111,113.

Apart from directly reducing insulin secretion, glucocorticoids also elicit inhibitory effects on insulin biosynthesis by inducing endoplasmic reticulum stress, which ultimately triggered apoptosis of INS-1E cells treated with glucocorticoids 112. Glucocorticoids might also increase cytotoxicity by accelerating the production of reactive oxygen species, which can also induce β-cell apoptosis 114. Despite the potential for glucocorticoid-induced β-cell apoptosis, glucocorticoid-induced diabetes mellitus in humans was found to be more related to insulin resistance and β-cell dysfunction rather than to decreased β-cell mass 115.

**In vivo studies.** Studies to identify the direct effects of glucocorticoids in vivo are particularly challenging to interpret owing to compensatory factors induced by long-term glucocorticoid exposure. A single oral dose of glucocorticoids acutely impaired insulin secretion in healthy individuals, whereas short-term treatment (up to 2 weeks) resulted in hyperinsulinaemia along with subtle changes in glycaemia 111,114. Healthy β-cells can increase insulin secretion to counterbalance glucocorticoid-induced insulin resistance as shown by increased β-cell function in rodent islets after in vivo glucocorticoid challenge (13 days) 111. Dexamethasone...
treatment of rats (5 days) also increases Ca2+-dependent protein kinase Ca (PKCa) signalling in islets, enhances GSIS capacity, and increases docking and exocytosis of preformed insulin granules19. Hyperinsulinaemia induced by dexamethasone treatment in rats (5 days) is accompanied by the expansion of β-cell mass in a dose-dependent manner120. However, in susceptible populations (such as those with obesity or a family history of T2DM), where β-cells are already overworked, the compensation by β-cells to a glucocorticoid challenge is lost15,16,121. Short-term (2–5 days) exposure to glucocorticoids in these individuals decreases β-cell insulin secretion and whole-body glucose disposal16,121. In agreement with these findings, GSIS was impaired with long-term (24 days) glucocorticoid treatment of obese Wistar and Zucker (fa/faq) rats, which led to the development of hyperglycaemia17,122.

Interpreting the long-term effects of glucocorticoids on β-cells can also be confounded by the effect of the underlying inflammatory condition that the glucocorticoids are prescribed to treat17,41,121. Intriguingly, high serum levels of cortisol (still within physiological range) are positively associated with β-cell defects and suppressed insulin secretion in the general population and in patients with Cushing syndrome124,125. In addition to these mechanisms by which glucocorticoids directly induce β-cell failure, glucocorticoids also indirectly promote β-cell lipotoxicity due to high plasma levels of NEFAs1.

**Bone**

Osteoporosis is one of the most well-established adverse effects of long-term glucocorticoid exposure (>3 months, osteoporosis risk depends on the dose)126. Glucocorticoid-induced osteoporosis results from the dual action of glucocorticoids on the suppression of bone-forming osteoblasts and the differentiation and maturation of bone-resorbing osteoclasts127. The effects of glucocorticoids on bone might contribute to hyperglycaemia in part due to elevated leptin secretion from adipose tissue as leptin suppresses the expression of osteocalcin, an insulin-sensitizing hormone that is secreted to impaired pancreatic β-cell proliferation and insulin expression128. Intriguingly, mice that lack osteocalcin develop glucose intolerance and insulin resistance due to impaired pancreatic β-cell proliferation and insulin expression19. Indeed, circulating levels of osteocalcin are associated with improved glycaemic control in patients with T2DM129. Furthermore, a single dose of glucocorticoid in humans is correlated with reduced serum levels of osteocalcin129. Mice with decreased glucocorticoid signalling in osteoblasts (achieved through targeted overexpression of 11β-HSD2 to inactive endogenous glucocorticoids) had higher levels of circulating osteocalcin and were protected against glucocorticoid-induced glucose and insulin intolerance compared with glucocorticoid-treated wild-type mice122. These findings demonstrate a partial role for the skeleton in the regulation of energy metabolism.

**Brain**

The development of glucocorticoid-induced obesity and diabetes mellitus is also partially mediated through appetite stimulation in the arcuate nucleus of the hypothalamus123. Glucocorticoids upregulate the mRNA expression of neuropeptide Y (NPY) and agouti-related peptide (AgRP) and increase the firing rate of their respective neurons, which stimulates appetite in rodents134,135. In mice, local administration of glucocorticoids to the arcuate nucleus was shown to induce hepatic insulin resistance through NPY release and signalling via the sympathetic nervous system136. Glucocorticoids stimulate leptin release from adipocytes into the circulation125. Furthermore, under physiological conditions, leptin suppresses appetite via leptin receptor signalling in NPY–AgRP neurons, which inhibits the release of these orexigenic peptides138. However, in rats, glucocorticoids were shown to synergistically antagonize the action of leptin by directly reducing leptin-dependent JAK–STAT signalling in the hypothalamus139. Aside from their orexigenic effects, glucocorticoids also promote increased caloric intake by shifting food preference towards high-calorie food that is high in fat or sugar (‘comfort food’). Rodents placed under restraint stress preferred lard and sucrose over normal chow140. Similarly, individuals with elevated circulating levels of cortisol (occurring after a stressful task) prefer high-calorie ‘comfort food’ over food that is lower in sugar and fat141. Over time, this extra caloric intake could contribute to a substantial increase in adiposity.

**Current treatment options**

Prior to starting glucocorticoid treatment, patients should be evaluated for risk factors for hyperglycaemia, including age, BMI and family history, and should be screened for pre-existing diabetes mellitus (measurements of fasting plasma glucose and HbA1c)38,142. At a minimum, plasma levels of glucose should be monitored 1–3 days after initiation of glucocorticoid treatment121. The frequency of monitoring plasma levels of glucose will increase if the patient is in hospital and/or has pre-existing T2DM121. Monitoring should continue at regular 3–6 month intervals for a year and then yearly thereafter. The criteria for the diagnosis of glucocorticoid-induced diabetes mellitus are similar to other types of diabetes mellitus: fasting plasma glucose concentration ≥7.0 mM, random plasma concentration of glucose ≥11.1 mM, HbA1c ≥6.5% (48 mmol/mol) or plasma glucose concentration ≥11.1 mM 2 h after an oral glucose tolerance test (OGTT)141. Glucocorticoid exposure has a more notable effect on postprandial glycaemia compared with fasting glucose141. Thus, the prevalence of glucocorticoid-induced hyperglycaemia is probably underestimated because fasting plasma glucose is more frequently assessed compared with the more time-consuming OGTT141. Determination of postprandial glycaemia 2 h after lunch and/or OGTT provides the most ideal measure to diagnose glucocorticoid-induced diabetes mellitus141,142. Treatment should be initiated when plasma levels of glucose are repeatedly ≥12 mM according to the management guideline established by the Joint British Diabetes Societies143. The goal of hypoglycaemic treatment in glucocorticoid-induced hyperglycaemia is to achieve glucose levels ≤10 mM143.
Table 1 | Hypoglycaemic agents in glucocorticoid-induced hyperglycaemia and diabetes mellitus

| Drug class                        | Advantages                                      | Disadvantages                                      | Evidence in patients with glucocorticoid-induced diabetes mellitus | Suitable for type of glucocorticoid drug* |
|-----------------------------------|-------------------------------------------------|---------------------------------------------------|------------------------------------------------------------------|------------------------------------------|
| Sulfonylureas                     | Immediate onset of action                       | Long acting; high risk of hypoglycaemia; not specific to postprandial glucose | Improved fasting glucose<sup>156</sup>                             | Intermediate-acting (two or more daily doses) or long-acting glucocorticoids; intra-articular glucocorticoids |
| Glinides                          | Immediate onset of action; short acting; targets postprandial glucose; low risk of hypoglycaemia | Frequent dosing; high cost                         | Improved postprandial glucose<sup>152,153</sup> and mean glucose<sup>152</sup>; improved mean HbA<sub>1c</sub> in combination with other immunosuppressants<sup>151</sup> | Short-acting glucocorticoids              |
| Incretin-based therapy: GLP1 receptor agonists | Immediate onset of action; targets postprandial glucose; low risk of hypoglycaemia | Limited evidence; gastrointestinal and renal adverse effects; high cost | Improved mean and postprandial glucose<sup>157,158</sup>; reduced the insulin dose and injection frequency in combination with basal-bolus insulin<sup>103</sup> | Intermediate-acting or long-acting glucocorticoids |
| Incretin-based therapy: DPP4is    | Immediate onset of action; targets postprandial glucose; low risk of hypoglycaemia | Contradictory evidence; high cost                  | Improved<sup>156,160</sup> or unaffected<sup>151,162</sup> postprandial glucose; improved mean glucose<sup>156</sup> and HbA<sub>1c</sub> levels<sup>159</sup> | Intermediate-acting or long-acting glucocorticoids |
| Metformin                         | Low risk of hypoglycaemia; low cost             | Slow onset of action; avoid use in renal impairment | Improved postprandial glucose<sup>156</sup>; improved AUC of glucose during OGTT<sup>164</sup>, fasting glucose and HbA<sub>1c</sub> levels<sup>158</sup> | Intermediate-acting glucocorticoids      |
| Thiazolidinediones                | Low risk of hypoglycaemia                       | Slow onset of action; promotes weight gain (shared adverse effects with glucocorticoids) | Improved AUC of glucose during OGTT and HbA<sub>1c</sub> levels<sup>152,164</sup> in combination with insulin<sup>114</sup> | Intermediate-acting glucocorticoids      |
| SGLT2is                           | Immediate onset of action; low risk of hypoglycaemia | Limited evidence; promotes bone fracture (shared adverse effects with glucocorticoids) | No improvement in mean glucose when used as an add-on to other hypoglycaemics<sup>115</sup> | Insufficient data (has not been tested without other hypoglycaemic agents) |
| a-Glucosidase inhibitors         | Immediate onset of action; targets postprandial glucose; low risk of hypoglycaemia | Limited evidence; only provides weak hypoglycaemic effect | Improved postprandial glucose levels in combination with glinides<sup>153</sup> | Insufficient data (has not been tested without other hypoglycaemic agents) |

AUC, area under the curve; DPP4is, dipeptidyl peptidase 4 inhibitors; GLP1, glucagon-like peptide 1; OGTT, oral glucose tolerance test; SGLT2is, sodium–glucose co-transporter type 2 inhibitors. *Short acting (for example, hydrocortisone, half-life of 8 h), intermediate acting (for example, prednisolone or methylprednisolone, half-life of 16–40 h), long acting (for example, dexamethasone or betamethasone, half-life of 36–54 h).

Few clinical trials have systematically investigated the efficacy of oral hypoglycaemic agents on glucocorticoid-induced hyperglycaemia. Currently, no one-size-fits-all consensus exists regarding the optimal treatment strategy for this condition owing to the myriad factors involved. Due to the slow onset of action and narrow flexibility in dose titration of many oral hypoglycaemic agents, it is difficult to match the hypoglycaemic agent to the hyperglycaemic oscillation induced by glucocorticoids<sup>1</sup>. Individualized treatments are needed that consider the type, dose, scheme and duration of action of the glucocorticoid used as well as underlying patient comorbidities, concurrent medication use and the severity of hyperglycaemia induced by glucocorticoid administration. Short- and intermediate-acting glucocorticoids (often administered transiently with a high initial dose and tapered over time) can lead to rapid and severe fluctuations in glycaemia, with peaks occurring within 4–8 h of the dose and decreasing during the night<sup>29,115</sup>. In response to this, hypoglycaemic agents with high potency and rapid onset should be used to avoid the risk of nocturnal hypoglycaemia<sup>11,29</sup>. For patients on long-acting glucocorticoids or those taking multiple daily doses, hyperglycaemia can persist over 24 h. As such, treatments are favoured that have a long duration of action and enable flexibility in dose adjustments without exacerbating other glucocorticoid-dependent adverse effects<sup>14</sup>. Treatments should be tailored to the pattern of glucocorticoid-induced hyperglycaemia by considering the type of glucocorticoid and the pharmacokinetics and pharmacodynamics of the different hypoglycaemic agents<sup>14</sup>.

Non-insulin glucose-lowering therapies

Oral hypoglycaemic drugs are generally reserved for those experiencing mild glucocorticoid-induced hyperglycaemia (fasting plasma concentration of glucose <11.1 mM) without a history of diabetes mellitus or with well-controlled diabetes mellitus<sup>13,14</sup>. Different hypoglycaemic treatment options have various advantages and disadvantages and considerations for use under different glucocorticoid treatment schemes (TABLE 1).

Sulfonylureas. Sulfonylureas act to increase insulin release from pancreatic β-cells by binding to and inhibiting ATP-sensitive K<sup>+</sup> channels<sup>14</sup>. Their mechanism and immediate onset of action is an asset as an
oral agent for the treatment of glucocorticoid-induced diabetes mellitus. However, they target fasting plasma levels of glucose rather than postprandial hyperglycaemia and, if used with short-acting glucocorticoids given as a single morning dose, their long effects and narrow therapeutic window result in a high risk of nocturnal hypoglycaemia. Therefore, sulfonylureas are not recommended for the management of glucocorticoid-induced hyperglycaemia and are only considered for patients treated with intermediate-acting or long-acting glucocorticoid preparations in two or more daily doses or intra-articular glucocorticoids.

Glinides. Glinides are secretagogues that stimulate insulin secretion while exerting a more rapid onset and shorter duration of action than sulfonylureas. As such, glinides provide improved flexibility in adapting to glucocorticoid-provoked postprandial hyperglycaemia and their use eliminates the possibility of nocturnal hypoglycaemia. Glinides were shown to effectively manage blood levels of glucose in 14 out of 23 transplant recipients with new-onset diabetes mellitus that occurred after exposure to low dose glucocorticoids in combination with other immunosuppressants. Retrospective studies further confirmed that glinides improved glucocorticoid-induced postprandial hyperglycaemia regardless of the dose and duration of glucocorticoid treatment (divided dose or high-dose pulse therapy). However, the frequent required dosing and cost have limited their use and the efficacy of glinides is reduced when insulin resistance is present. Therefore, a combination of glinides with insulin sensitizers (metformin or thiazolidinediones) might be beneficial to control glucocorticoid-induced hyperglycaemia. Interestingly, the insulin-sensitizing thiazolidinediones (described later) induce CYP2C8 and CYP3A4 liver enzyme activity. If thiazolidinediones are combined with a glinide, this effect might result in a potential drug–drug interaction due to metabolism by the same enzymes.

Incretin-based therapies. Incretin hormones are peptides released by enteroendocrine cells in the gut following nutrient ingestion that stimulate insulin secretion. Glucagon-like peptide 1 (GLP1) receptor agonists and dipeptidyl peptidase 4 inhibitors (DPP4is) are incretin-based therapies that control hyperglycaemia by enhancing insulin secretion and glucose uptake into peripheral tissues, inhibiting glucagon secretion and decreasing gastric emptying. In particular, DPP4is enable the release of insulin postprandially by elevating the circulating levels of GLP1, thus specifically targeting postprandial glucose levels. Indeed, exenatide (a GLP1 receptor agonist) has been reported to efficaciously treat glucocorticoid-evoked postprandial hyperglycaemia in both healthy individuals and those with T2DM. DPP4is are also effective for the treatment of glucocorticoid-induced new-onset diabetes mellitus, yet contradicting reports exist that question their efficacy to prevent glucocorticoid-augmented postprandial hyperglycaemia. GLP1 receptor agonists are associated with more potent hypoglycaemic effects compared with DPP4is in patients with T2DM. Of note, injectable GLP1 receptor agonists have substantial gastrointestinal adverse effects, which make them less well tolerated compared with DPP4is. GLP1 receptor agonists should be used cautiously in patients with glucocorticoid-induced hyperglycaemia after renal transplantation owing to the potential for acute renal injury that is secondary to plasma volume contraction.

The immediate onset of action of incretin-based therapies without risk of hypoglycaemia and their specificity towards controlling postprandial glucose could enable these drugs to become frontline hypoglycaemics for patients with glucocorticoid-induced diabetes mellitus. They are particularly suitable for patients treated with a single daily dose of intermediate-acting or long-acting glucocorticoids, either transiently or over a long-term period. GLP1 agonists also have beneficial effects on body weight reduction and blood pressure, which suggests potential additive benefits towards glucocorticoid-induced secondary complications. However, evidence of incretin-based therapies providing long-term efficacy towards glucocorticoid-induced hyperglycaemia remains unclear. Furthermore, potential relapse might occur as observed in patients with T2DM who were treated with sitagliptin (a DPP4i) after 6 months. The paucity of evidence confirming the efficacy and safety of the incretin-based therapies in treating glucocorticoid-induced diabetes mellitus has limited their use and thus future studies are essential.

Insulin-sensitizing therapies

Metformin. Metformin has long been recommended as the first-line therapy for the treatment of T2DM. The drug induces a minimal risk of hypoglycaemia and limits glucocorticoid-induced hepatic and peripheral insulin resistance. Metformin greatly improves hepatic insulin sensitivity by counteracting glucogenesis and lipogenesis in the liver while increasing GLP1 secretion and glucose utilization in the gastrointestinal tract, thereby lowering glycaemia. Despite widespread use in T2DM, evidence of the effectiveness of metformin to counterbalance glucocorticoid treatment is fairly scarce. Nonetheless, glucocorticoid-mediated postprandial hyperglycaemia and insulin resistance are decreased with metformin use in patients receiving glucocorticoids who do not have diabetes mellitus. Due to its slow onset of action, metformin is considered a favourable option when low doses of intermediate-acting glucocorticoids are administered over the long term. Metformin remains important for combination therapy with other oral hypoglycaemic drugs because it is not metabolized by cytochrome P450 enzymes, has minimal adverse effects and is low cost. Of note, metformin is contraindicated in individuals with impaired renal function, and should therefore be avoided in patients receiving glucocorticoids after renal transplantation.

Thiazolidinediones. Thiazolidinediones are robust insulin sensitizers and therefore affect the action of glucocorticoids on plasma levels of glucose by improving both hepatic and peripheral insulin sensitivity without
inducing hypoglycaemia. In addition to improving insulin sensitivity, thiazolidinediones have the ability to preserve β-cell function. Similar to metformin, their slow onset of action limits the use of thiazolidinediones for long-term treatment in patients with glucocorticoid-induced hyperglycaemia. In patients on long-term, low-dose glucocorticoid therapy, 6 months of treatment with pioglitazone statistically significantly reduced plasma glucose concentration 2 h post-OGTT, HbA1c, and homeostasis model assessment of insulin resistance (HOMA-IR). Thiazolidinediones also improve diabetes-related parameters in patients with severe glucocorticoid-induced hyperglycaemia when administered in combination with insulin. However, thiazolidinediones are less appealing compared with metformin owing to their overlapping adverse effects with glucocorticoids, including weight gain, increased risk of bone fractures and fluid retention. Therefore, the benefits must be balanced against their complications when considering thiazolidinediones as treatment options for managing glucocorticoid-induced hyperglycaemia.

**Therapies with other mechanisms of action**

**Sodium–glucose co-transporter type 2 inhibitors.** Sodium–glucose co-transporter type 2 inhibitors (SGLT2is) lower plasma levels of glucose by reducing glucose reabsorption in the kidney. Their immediate onset of action means they can alleviate glucocorticoid-induced hyperglycaemia in patients with pre-existing T2DM when they were challenged with a short-term (5–14 days) high dose of glucocorticoid. SGLT2is are also associated with risks of urinary tract and genital infections, and this risk could be exacerbated by glucocorticoid-mediated immunosuppression. The risk of glucocorticoid-induced osteoporosis might also be enhanced due to the potential of SGLT2is to enhance bone resorption. Finally, whether SGLT2is alone can alleviate glucocorticoid-induced hyperglycaemia remains to be tested.

**α-Glucosidase inhibitors.** α-Glucosidase inhibitors (AGIs) inhibit the breakdown of complex carbohydrates and delay the absorption of glucose in the gastrointestinal tract, thus reducing postprandial plasma levels of glucose. As a second-line intervention to metformin, AGIs are mainly prescribed in combination with other hypoglycaemic agents owing to their non-cytochrome P450-dependent metabolism and weak hypoglycaemic effect when administered alone. The combination of glinides and AGIs was shown to improve glucocorticoid-mediated postprandial hyperglycaemia in patients with rheumatoid arthritis.

**Insulin**

Insulin therapy should be initiated in those patients who are treated with glucocorticoids and have persistent glycaemic oscillations ≥10 mM as recommended by the ADA. Insulin should also be used when non-insulin hypoglycaemic therapy fails to adequately control glycaemia in patients treated with glucocorticoids who have pre-existing T2DM. Insulin therapy can efficaciously provide immediate targeting of postprandial hyperglycaemia and flexibility in dosing based on food intake. Insulin regimens are tailored to glucocorticoid dosing schedules and patient BMI and hyperglycaemic profile. In patients with pre-existing diabetes mellitus who already require insulin, a 20% increment in daily insulin dose is generally required upon the addition of

| Insulin schedules | Onset of action | Duration | Advantages | Disadvantages | Suitable for type of glucocorticoid drug* |
|-------------------|----------------|----------|------------|--------------|----------------------------------------|
| Basal insulin (detemir or glargine) | 1–4 h | Long acting, up to 24 h | Low risk of hypoglycaemia | Not specific to postprandial glucose | Intermediate-acting (2 or more daily doses), or long-acting glucocorticoids |
| Basal insulin (NPH) | 1–2 h | Intermediate acting, ≥14 h | Activity profile closely resembles glucocorticoid-induced hyperglycaemia | Not specific to postprandial glucose | Intermediate-acting glucocorticoids |
| Prandial (bolus) insulin | 15–60 min | Rapid and short acting, 3–8 h | Immediate onset of action; targets postprandial glucose; can be combined with basal insulin for severe glucocorticoid-induced hyperglycaemia | Limited flexibility in the timing of administration | Short-acting glucocorticoids |
| Basal-bolus | 15–60 min for bolus | Rapid and long acting, up to 24 h | Flexibility in dose adjustment; useful for severe or persistent glucocorticoid-induced hyperglycaemia | Multiple daily injections | Use is based on severity of hyperglycaemia (not on type of glucocorticoid) |

NPH, neutral protamine Hagedorn. *Short acting (for example, hydrocortisone, half-life of 8 h), intermediate acting (for example, prednisolone or methylprednisolone, half-life of 16–40 h), long acting (for example, dexamethasone or betamethasone, half-life of 36–54 h).
glucocorticoid therapy in order to achieve similar glycaemic control\textsuperscript{146}. Of note, changes to the glucocorticoid dose might not immediately result in corresponding effects on blood levels of glucose, particularly in patients with pre-existing diabetes mellitus\textsuperscript{22}. As such, the insulin dose used should be carefully titrated to match the glycaemic oscillation of individual patients to provide optimal glucose control.

The use of basal and bolus insulin in combination delivers insulin that most closely resembles its physiological pancreatic release to maintain euglycaemia in both fasting and postprandial states\textsuperscript{182}. For inpatients with severe or persistent hyperglycaemia due to high glucocorticoid doses, multiple daily doses or long-acting glucocorticoid use, basal-bolus insulin should be initiated\textsuperscript{219,224}. These regimens offer great flexibility in dose titration, as hospital staff can make adjustments based on preprandial glycaemic reading, anticipated carbohydrate intake and interpatient insulin sensitivity\textsuperscript{183}. However, as multiple daily injections are required of long-acting basal insulin and rapid-acting bolus insulin administered preprandially\textsuperscript{183}, it is impractical for the outpatient with new-onset glucocorticoid-induced hyperglycaemia to manage once discharged. Education on self-injections, stringent glucose monitoring and concern over nocturnal hyperglycaemia can be major drawbacks for insulin therapy, especially if glucocorticoids are required only over a short term\textsuperscript{234}.

For outpatients who are treated with long-term, once-daily glucocorticoids, for whom only postprandial glucose is elevated, neutral protamine Hagedorn (NPH) insulin is a preferable option that can be administered at the same time as their glucocorticoid in the morning\textsuperscript{13,234}. These insulin preparations have a closely aligned temporal profile (peak 4–10 h, duration of action ≥14 h) with the hyperglycaemic excursion induced by intermediate-acting glucocorticoids\textsuperscript{182}. When twice-daily intermediate-acting or long-acting glucocorticoids are administered, the total dose of NPH insulin can be divided\textsuperscript{219} or substituted for long-acting basal insulin (insulin detemir or glargine), which can adequately match the pattern of glucocorticoid-evoked hyperglycaemia\textsuperscript{114}. Oral hypoglycaemic agents can be added to insulin therapy when patients continue to exhibit severe or persistent hyperglycaemia (HbA\textsubscript{1c} >9\%)\textsuperscript{108}. Insulin sensitizers, such as metformin and thiazolidinediones, are the most frequently prescribed in combination with insulin that can provide further glycaemic benefits under chronic glucocorticoid exposure\textsuperscript{119}.

### Novel pharmacological targets

The unparalleled efficacy of glucocorticoids for the treatment of inflammatory diseases has led to tremendous interest by pharmaceutical companies to develop compounds that could eliminate their diabetogenic effects while preserving their anti-inflammatory functions. Two such approaches, selective glucocorticoid receptor agonists or selective glucocorticoid receptor modulators (Box 3) and 11β-HSD1 inhibitors (Box 4), have made it to clinical trials; however, neither has yet emerged as being clearly superior to glucocorticoids as currently used in practice. The limited dissociative effects of selective glucocorticoid receptor agonists or selective glucocorticoid receptor modulators and the limited efficacy of 11β-HSD1 inhibitors have challenged their continued clinical development as they have not achieved clear superiority over conventional glucocorticoids. Discoveries of novel therapeutic targets can distinguish the beneficial effects of glucocorticoids from their secondary complications have sparked new interest in the field (FIG. 2).

#### Liver X receptor-β

As members of the nuclear receptor superfamily of transcription factors, liver X receptor-α (LXRA) and LXRβ control cholesterol homeostasis by sensing...
Whole-body knockout of the gene encoding LXRβ (*Nr1h2*) (but not LXRα, encoded by *Nr1h3*) and/or pharmacological inhibition of LXRβ protects mice against hyperglycaemia, hyperinsulinaemia and hepatic steatosis following glucocorticoid treatment via suppression of genes involved in gluconeogenesis[^184,185]. Notably, the immunosuppressive effects of glucocorticoids are unaltered by LXRβ antagonism. Loss of LXRβ specifically in adipose tissue was reported in a 2021 study to attenuate glucocorticoid-induced lipogenesis and lipolysis in mice and improve systemic insulin tolerance by decreasing NEFA shuttling to the liver[^186]. Limitations of targeting LXRβ to minimize the diabetogenic effects of glucocorticoids include the development of LXRβ isoform-selective inhibitors (owing to high similarity with LXRα) and ensuring no adverse effects occur on whole-body cholesterol efflux (although this function is mainly mediated by LXRα[^187]).

**E47**

The basic helix–loop–helix transcription factor E47 is required for efficient recruitment of glucocorticoid receptors and coregulators to a subset of lipid and glucose metabolic gene promoters in the liver[^188]. Loss of E47 specifically from rodent livers abolished the development of glucocorticoid-induced hyperglycaemia and hepatic steatosis[^188]. Both LXRβ and E47 could plausibly synchronously regulate the recruitment of glucocorticoid receptors to target genes involved in gluconeogenesis such as *Pck1*. Due to the ubiquitous expression of LXRβ and E47, targeting these proteins might necessitate the development of tissue-specific antagonists.
Coregulators of glucocorticoid receptor
The loss of the glucocorticoid receptor coactivator euchromatic histone methyltransferase 2 in the liver was associated with aggravated glucocorticoid-induced hepatic insulin resistance in mice190. Another coactivator of the glucocorticoid receptor, arginine and glutamate-rich protein 1 (ARG1)191, is critical in mediating the recruitment of glucocorticoid receptors to the gluconeogenic Pck1 promoter192. Thus, targeting specific members of the glucocorticoid receptor co-regulator complex remains a fruitful area for future investigation.

Histone deacetylase 6
In the absence of ligand, the glucocorticoid receptor is bound to chaperone proteins in the cytoplasm, including heat shock protein 90 (HSP90)192. Histone deacetylase 6 (HDAC6) deacetylates HSP90, thereby enabling its interaction with the co-chaperone p23, which is essential for the ligand-binding activity of glucocorticoid receptor. Inactivation of HDAC6 results in HSP90 hyperacetylation and decreases ligand binding to the glucocorticoid receptor due to the dissociation of p23 (REF192). Loss of HDAC6 in mice partially ameliorated glucocorticoid-induced hyperglycaemia and insulin resistance by impairing translocation of glucocorticoid receptors and subsequent glucocorticoid receptor-mediated gluconeogenesis in the liver193. In 2021, HDAC6 was discovered to deacetylate the histone arginine demethylase PRMT5, which inhibits its activity194. As PRMT5 increases chromatin accessibility near gluconeogenic promoters195, this finding could be an additional mechanism by which HDAC6 inhibition constrains glucocorticoid-induced hyperglycaemia.

Serotonin signalling
Plasma levels of serotonin (5-hydroxytryptamine or 5-HT) were found to be elevated in patients with T2DM and seemingly contribute to peripheral vascular disease196. In rodents, glucocorticoids can promote insulin resistance by upregulating serotonin synthesis and serotonin receptor (5-HT,R) expression in liver and visceral adipose tissue197. In rats, treatment with a serotonin synthetic inhibitor and/or 5-HT₂R antagonist reversed glucocorticoid-mediated hepatic gluconeogenesis, steatosis and insulin resistance198. A key question that remains for therapeutic targeting of the serotonin signalling pathway in this context will be whether inhibition can be achieved without altering serotonin transmission in the central nervous system.

Ceramide synthesis
The ability of glucocorticoids to upregulate the expression of genes involved in ceramide synthesis, such as that encoding serine palmitoyltransferase (Sptlc2), provides a novel approach to protect against glucocorticoid-dependent disruption in glucose homeostasis199. Ceramide-induced activation of protein kinase Cζ (PKCζ) promotes hepatic insulin resistance by inhibiting PKB–AKT downstream of the insulin receptor199. In rodents, pharmacological inhibition of serine palmitoyltransferase by myriocin or PKCζ by 2-acetyl-1,3-cyclopentanediol limits ceramide biosynthesis and signalling, which in turn reduces glucocorticoid-mediated hepatic glucose output and insulin resistance. Despite the inverse correlation between plasma levels of ceramides and improved glucose homeostasis, ceramides have a wide range of biological functions at several cellular growth checkpoints. Therefore, pharmacological targeting of ceramides will first require prudent examination of the specific roles of different ceramide species200.

Conclusions
Glucocorticoids are indispensable for their powerful immunosuppressive and anti-inflammatory effects. However, the adverse metabolic effects of long-term use, including hyperglycaemia and diabetes mellitus, have diminished their therapeutic value. The underlying molecular mechanisms of glucocorticoid-induced hyperglycaemia are complex and involve multiple organs. Organs and tissues either fail to remain responsive to insulin or promote insulin resistance via inter-organ crosstalk, which makes it difficult to predict which patients will develop adverse metabolic effects. This limitation in knowledge has resulted in the poor clinical management of hyperglycaemia and diabetes mellitus as a result of glucocorticoid exposure. Universal guidelines should be established that consider the variations in glucocorticoid therapy, genetic predisposition, comorbidities and therapeutic tolerance of individual patients. The incorporation of patient education with respect to routine glucose monitoring upon the prescription of glucocorticoids will help combat glucocorticoid-induced hyperglycaemia and diabetes mellitus. Future studies that provide a deeper understanding of the mechanism of action of glucocorticoids could lead to the development of novel therapeutic strategies to minimize the diabetogenic effects while sparing the beneficial immunosuppressive effects of glucocorticoids.

Published online: 18 May 2022

References
1. Sapolsky, R. M., Romero, L. M. & Munck, A. U. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr. Rev. 21, 55–89 (2000).
2. Hench, P. S. et al. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Proc. Staff Meet. Mayo Clin. 24, 181–197 (1949).
3. Cain, D. W. & Gillovski, J. A. Immune regulation by glucocorticoids. Nat. Rev. Immunol. 17, 253–267 (2017).
4. van Staa, T. P. et al. Use of oral corticosteroids in the United Kingdom. J. R. Med. 93, 105–111 (2000).
5. Overman, R. A., Veh, J. Y. & Deal, C. L. Prevalence of oral glucocorticoid usage in the United States: a general population perspective. Arthritis Care Res. 65, 294–298 (2013).
6. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA 324, 1350–1361 (2020).
7. Liu, D. et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin. Immunol. 9, 30 (2013).
8. van Raalte, D. H. & Diamant, M. Steroid diabetes: from mechanism to treatment? Neth. J. Med. 72, 62–72 (2014).
9. Guilford, M. C., Charlton, J. & Latiniowc, R. Risk of diabetes associated with prescribed glucocorticoids in a large population. Diabetes Care 29, 2728–2729 (2006).
10. Rizza, R. A., Mandarino, L. J. & Gerich, J. E. Cortisone-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a postreceptor defect of insulin action. J. Clin. Endocrinol. Metab. 54, 131–138 (1982).
11. Pagano, G. et al. An in vivo and in vitro study of the mechanism of prednisone-induced insulin resistance in healthy subjects. J. Clin. Invest. 72, 1814–1820 (1983).
12. Liu, X. X. et al. Hyperglycemia induced by glucocorticoids in nondiabetic patients: a meta-analysis. Am. Nutr. Metab. 65, 324–332 (2014).
sodium phosphate on blood glucose levels in controlled diabetic patients with symptomatic osteoarthropathy of the knee. Clin. Rheumatol. 28, 85–87 (2009).

13. Perez, A. et al. Glucocorticoid-induced hyperglycemia. J. Diabetes 6, 9–20 (2014).

14. A thorough guideline that provides insight into the management of glucocorticoid-induced hyperglycemia to treatment strategies, based on the pathophysiology observed and dosing regimens of glucocorticoids used.

15. Novell, N. & DeSante, M. L., Nieman, K. L. Cushing’s syndrome. Lancet 367, 1605–1617 (2006).

16. Scipioni, E., Tzitzikas, M., Foti, M. & Bocarsly, M. Glucose metabolism abnormalities in Cushing syndrome: from molecular basis to clinical management. Endocr. Rev. 38, 169–199 (2017).

17. Hechter, M. D., Wolf, I. M., Sanchez, E. R., Witchel, S. F. & DeFranco, D. B. Glucocorticoid receptor physiology. Rev. Endocr. Metab. Disord. 8, 321–330 (2007).

18. Grooten, L. M., Thompson, C. G. & Mashiah, S. Glucocorticoid receptor recruitment to steroid response elements. Mol. Cell. Endocrinol. 200, 550–555 (2000).

19. Puissguer, P. et al. Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature 451, 479–485 (2008).

20. Hall, R. K., Wang, X. L., George, L., Koch, S. R. & Graner, D. K. Insulin represses phosphoenolpyruvate carboxykinase gene transcription by causing the rapid disruption of an active transcription complex: a potential epigenetic effect. Mol. Endocrinol. 21, 350–356 (2007).

21. Andrews, R. C. & Walker, B. R. Glucocorticoids and insulin resistance: old hormones, new targets. Nat. Rev. Endocrinol. 6, 513–529 (2009).

22. Rojas, P. A., Himata, A. N. & M. J. Regulation of insulin receptor substrate-2 tyrosine phosphorylation in animal models of insulin resistance. Endocr. Rev. 21, 85–114 (2000).

23. Titchenel, P. M., Lazzar, M. A. & Birnbaum, M. J. Unraveling the regulation of hepatic metabolism by insulin. Trends Endocrinol. Metab. 28, 497–505 (2017).

24. Lambh, R. A., Rapal, A. & Ismail-Begi, F. Glucocorticoid-induced fatty liver disease. Diabetes Metab. Syndr. Obes. 13, 11160–11165 (2020).

25. Samuel, V. T. & Shulman, G. I. The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J. Clin. Invest. 126, 12–22 (2016).

26. Holland, W. L. et al. Inhibition of ceramic synthesis ameliorates glucocorticoid, saturated-fat, and obesity-induced insulin resistance. Cell Metab. 5, 167–179 (2007).

27. Key identifying the contribution of ceramide to glucocorticoid-induced insulin resistance, which highlights the potential of targeting ceramide pharmacologically to eliminate glucocorticoid-dependent dysfunction in glucocorticoid-induced insulin resistance.

28. DeFrondo, R. A. et al. The effect of insulin on the disposal of intravenous glucose. Results from indirect calorimetry and femoral venous catheterization. Diabetes 30, 1000–1007 (1981).

29. Giorgino, F., Almaitouz, A., Goodyear, L. J. & Smith, R. J. Glucocorticoid-induced insulin resistance: receptor and substrate IRS-1 tyrosine phosphorylation in rat skeletal muscle in vivo. J. Clin. Invest. 119, 2030–2039 (2009).

30. Saad, M. J., Folli, F., Kahn, J. A. & Kahn, C. R. Modification of insulin receptor, insulin receptor substrate-1, and phosphatidylinositol 3-kinase in liver and muscle of dexamethasone-treated rats. J. Clin. Invest. 92, 2065–2072 (1993).

31. Ruzin, J., Wajng A., & S. Jensen. Glucocorticoid-induced insulin resistance in skeletal muscles: defects in insulin signaling and the effects of a selective glycogen synthase kinase-3 inhibitor. J. Clin. Endocrinol. Metab. 86, 4712–4719 (2010).

32. Blackman, D., Hux, J. & Mamdani, M. Quantification of the risk of corticosteroid-induced diabetes mellitus among the elderly. J. Gen. Intern. Med. 17, 717–720 (2002).

33. Habib, G. & Safia, A. The effect of intra-articular injection of betamethasone acetate/betamethasone sodium phosphate on blood glucose levels in controlled diabetic patients with symptomatic osteoarthropathy of the knee. Clin. Rheumatol. 28, 85–87 (2009).

34. Fleming, P., Drazek, L. & Shaw, J. C. Hyperglycemia following intraarticular glucocorticoid injection in a patient with type I diabetes mellitus. J. Cutan. Med. Surg. 18, 275–276 (2014).

35. Hjelmesaeth, J. & DeFranco, D. B. Glucocorticoid-induced hyperglycemia: from high-dose glucocorticoid use in nongenitally ill patients. Diabetol. Metab. Syndr. 5, 18 (2013).

36. Nakamura, H., Fujieda, Y., Nakamura, A. & Atsumi, T. H. How to manage glucocorticoid-induced hyperglycemia? Rev. Mol. Med. 51, 519–528 (2021).

37. Meta-analyses provide a comprehensive review into the management of glucocorticoid-induced hyperglycaemia from the point of view of rheumatology.

38. Shaharir, S. S., Gafar, A. H., Said, M. S. & Kong, N. C. Steroid-induced diabetes mellitus in systemic lupus erythematosus patients: analysis from a Malaysian multi-ethnic lupus cohort. Int. J. Rheum. Dis. 18, 541–547 (2015).

39. Wajngot, A., Gacca, A., Grill, V., Vanier, M. & Efendic, S. The diabetogenic effects of glucocorticoids are more pronounced in low-than in high-insulin responders. Proc. Natl. Acad. Sci. USA 89, 6035–6039 (1992).

40. Larson, S. H. & Roberts, A. M. Insulin resistant subjects after meniskitis and adaptation to short-term dexamethasone induced reduction in insulin sensitivity. Diabetologia 42, 935–942 (1999).

41. Braithwaite, S. S., Barr, W. G., Rahman, A. & Quddusi, S. Managing diabetes during glucocorticoid therapy. How is it done? Postgrad Med. https://doi.org/10.3810/pgm.1998.11.426 (1998).

42. Yang, X. & Fasting plasma glucose levels predict steroid-induced abnormal glucose metabolism in patients with non-diabetic chronic kidney disease: a prospective cohort study. Am. J. Nephrol. 41, 107–115 (2015).

43. Katsuyma, Y. et al. Risk factors for the development of glucocorticoid-induced diabetes mellitus. Diabetes Res. Clin. Pract. 108, 275–279 (2015).

44. Depczynski, B., Daly, B., Campbell, L. V., Chisolm, D. J. & Keogh, A. Predicting the occurrence of diabetes mellitus in recipients of heart transplants. Diabetol. Med. 17, 15–19 (2000).

45. Henrikson, J. E., Alford, F. W., Ward, G. M. & Beck-Nielsen, H. Risk and mechanism of dexamethasone induced deterioration of glucose tolerance in non-diabetic first degree relatives of NIDDM patients. Diabetologia 40, 1439–1448 (1997).

46. Miyawaki, A. et al. Observational study of glucocorticoid-induced diabetes mellitus with IGA nephropathy treated with tonsillectomy plus methylprednisolone pulse therapy. PLoS One 12, e0178018 (2017).

47. Simmons, L. R., Molyneaux, L., Yue, D. K. & Chuai, E. I. Smaller and smaller: is it still unmasking of type 2 diabetes? ISRN Endocrinol. 2012, 910905 (2012).

48. Hu, W. et al. Individual-specific functional epigenomics reveals genetic determinants of adverse metabolic effects of glucocorticoids. Cell Metab. 33, 1502–1509 (2021).

49. This study discovers genetic variations within the population in predicting individual-specific metabolic responses to glucocorticoid therapy, including hyperglycemia and diabetes mellitus.

50. Sours, J. et al. Glucocorticoid-induced diabetes mellitus in patients with systemic lupus erythematosus treated with high-dose glucocorticoid therapy. Lupus 20, 1027–1034 (2011).

51. Frazier, B., Hisao, C. W., Deuster, P. & Poth, M. African Americans and Caucasian Americans: differences in glucocorticoid-induced insulin resistance. Horm. Metab. Res. 42, 887–891 (2010).

52. Binett, C., Ruchat, S., Nicold, N. & Tappe, L. Dexamethasone-induced insulin resistance shows no gender difference in healthy humans. Diabetes Metab. Transplantation 8, 321–326 (2020).

53. Vegopoulos, A. & Herzog, S. C. Metabolism and metabolic diseases. Mol. Cell. Endocrinol. 2019, 915–919 (2019).

54. This review discusses all aspects of whole-body and tissue-specific glucocorticoid action, much of which is still not fully understood today.
a randomised, double-blind, multicentre, phase IIb study. RMD Open. 5, e000889 (2019).

215. Safy, M. et al. Efficacy and safety of selective glucocorticoid receptor modulators in comparison to glucocorticoids in arthritis, a systematic review. PLoS One 12, e0188810 (2017).

216. Myrback, T. H. et al. Effects of a selective glucocorticoid receptor modulator (AZD9567) versus prednisolone in healthy volunteers: two phase 1, single-blind, randomised controlled trials. Lancet Rheumatol. 2, E31–E41 (2020).

217. US National Library of Medicine. ClinicalTrials.gov https://ClinicalTrials.gov/show/NCT04556760 (2020).

218. Masuzaki, H. et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 294, 2166–2170 (2001).

219. Tomlinson, J. W. et al. Impaired glucose tolerance and insulin resistance are associated with increased adipose 11beta-hydroxysteroid dehydrogenase type 1 expression and elevated hepatic 5alpha-reductase activity. Diabetes 57, 2652–2660 (2008).

220. Peng, K. et al. 11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) mediates insulin resistance through JNK activation in adipocytes. Sci. Rep. 6, 57160 (2016).

221. Morgan, S. A. et al. 11β-HSD1 is the major regulator of the tissue-specific effects of circulating glucocorticoid excess. Proc. Natl Acad. Sci. USA 111, E2482–E2491 (2014).

222. Rosenstock, J. et al. The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13579 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. Diabetes Care 35, 1516–1522 (2010).

223. Heise, T. et al. Safety, efficacy and weight effect of two 11beta-HSD1 inhibitors in metformin-treated patients with type 2 diabetes. Diabetes Obes. Metab. 16, 1070–1077 (2014).

224. Feg, P. D. et al. Effects of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome. Diabetes Obes. Metab. 13, 498–504 (2011).

225. US National Library of Medicine. ClinicalTrials.gov https://ClinicalTrials.gov/show/NCT03111810 (2017).

Acknowledgements
The authors gratefully acknowledge the support of research programmes from the Canadian Institutes of Health Research (PJT-156194 and PJT-156159) and the Natural Science and Engineering Research Council of Canada (RGPIN-2020-07212). J.X.L. is a recipient of the Ontario Graduate Scholarship. The authors thank Dr Ahmed Aman (Ontario Institute for Cancer Research) for providing guidance on therapeutics currently under development.

Author contributions
The authors contributed equally to all aspects of the article.

Competing interests
C.L.C. is a co-inventor on US9428753 patent entitled “Use of LXR antagonists for treatment of side effects of elevated glucocorticoid levels”. J.X.L. declares no competing interests.

Peer review information
Nature Reviews Endocrinology thanks the anonymous reviewer(s) for their contribution to the peer review of this work.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© Crown 2022